| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥2915.3B | ¥2669.3B | +9.2% |
| Operating Income | ¥126.3B | ¥149.1B | -15.3% |
| Ordinary Income | ¥125.5B | ¥160.7B | -21.8% |
| Net Income | ¥72.0B | ¥130.5B | -44.8% |
| ROE | 2.4% | 4.3% | - |
FY2025 Q3 cumulative results: Revenue 291.5B yen (YoY +9.2%), Operating Income 12.6B yen (YoY -15.3%), Ordinary Income 12.6B yen (YoY -21.8%), Net Income 7.2B yen (YoY -44.8%). The company exhibited a revenue up/profit down pattern, with top-line growth driven by expansion of the Takara Shuzo International Group segment, while bottom-line profitability deteriorated significantly due to elevated SG&A expenses, increased impairment losses of 3.87B yen in the Takara Bio segment, and higher effective tax rate of 53.7%. Despite revenue expansion of 24.6B yen YoY, operating income declined by 2.3B yen, resulting in operating margin compression to 4.3% from prior year 5.6%. Extraordinary items including gain on sale of securities 6.4B yen and impairment loss 3.9B yen contributed to net income volatility.
Revenue increased 9.2% YoY to 291.5B yen, with all three reporting segments contributing to growth. The Takara Shuzo International Group segment grew 20.2% YoY to 160.0B yen, representing 54.9% of consolidated revenue, driven by overseas market expansion including the acquisition of Kagerer & Co. GmbH in Germany (goodwill of 1.48B yen recorded provisionally). The Takara Shuzo domestic segment revenue declined slightly by 2.1% to 93.3B yen, representing 32.0% of revenue, reflecting challenges in the domestic alcoholic beverage market. The Takara Bio Group segment declined 3.0% to 28.4B yen (9.7% of revenue), impacted by slower demand in research reagents. The Other segment, comprising logistics, wine import, and real estate, grew 7.7% to 9.9B yen (3.4% of revenue).
Operating income declined 15.3% YoY to 12.6B yen despite revenue growth, reflecting operating margin compression from 5.6% to 4.3%. Gross profit increased 9.7% to 94.2B yen with stable gross margin at 32.3%, but SG&A expenses increased 12.0% to 81.6B yen (28.0% of revenue versus 27.3% prior year), outpacing revenue growth. The SG&A increase reflects integration costs from M&A activities, expanded marketing expenses for international operations, and group reorganization costs. Operating leverage deteriorated as the company failed to convert revenue growth into proportional profit growth.
Ordinary income declined 21.8% YoY to 12.6B yen, with non-operating net expense of 0.1B yen (versus prior year net income of 1.2B yen). Non-operating income totaled 1.9B yen including dividend income of 0.9B yen and interest income of 0.5B yen, while non-operating expenses increased to 2.0B yen primarily from interest expense of 1.1B yen. Net income declined sharply by 44.8% to 7.2B yen, with the gap between ordinary income 12.6B yen and net income 7.2B yen explained by extraordinary items and tax burden. Extraordinary income of 7.2B yen included gain on sale of securities 6.4B yen (non-recurring), offset by extraordinary losses of 4.2B yen including impairment loss 3.9B yen primarily in the Takara Bio segment. Income tax expense of 8.4B yen represented an effective tax rate of 53.7%, significantly elevated from normal levels due to non-deductible impairment and jurisdictional tax effects. Net income attributable to non-controlling interests was negative 3.4B yen, indicating losses at subsidiary level.
The company exhibited a revenue up/profit down pattern, with structural profitability challenges including elevated SG&A ratio, substantial non-recurring impairment charges, and inefficient tax management requiring operational improvement focus.
The Takara Shuzo International Group is the core business representing 54.9% of revenue, generating 160.0B yen revenue (YoY +20.2%) and 9.8B yen operating income with 6.1% margin. This segment drove consolidated revenue growth through geographic expansion and the Kagerer acquisition, though margin remained modest at 6.1%. The Takara Shuzo domestic segment contributed 93.3B yen revenue (YoY -2.1%) with 5.8B yen operating income and 6.2% margin, slightly above the international segment. Domestic revenue contraction reflects mature market conditions and shifting consumer preferences. The Takara Bio Group recorded 28.4B yen revenue (YoY -3.0%) with operating loss of 4.9B yen (margin negative 17.1%), representing a significant deterioration from prior year loss of 1.5B yen. The segment's loss widening was driven by impairment charges of 3.87B yen related to underperforming assets and the acquisition of Curio Bioscience Inc. (goodwill 0.63B yen provisionally recorded). The segment's negative margin indicates structural challenges requiring turnaround actions. Segment margin differences are material, with domestic and international alcoholic beverage operations both achieving approximately 6% margins while the bio-technology segment remains deeply unprofitable. The Other segment contributed 9.9B yen revenue with operating income information absorbed in corporate adjustments. Unallocated corporate expenses totaled 0.9B yen versus 0.5B yen prior year, reflecting increased holding company costs.
[Profitability] ROE 2.4% declined substantially from prior year levels, with operating margin 4.3% representing 1.3 percentage point compression from 5.6% YoY. Net profit margin 2.5% contracted from prior year 4.9%, reflecting combined impact of operating margin deterioration, increased impairment charges, and elevated effective tax rate of 53.7%. Gross margin remained stable at 32.3%, indicating cost pressures manifested primarily in operating expenses rather than input costs. [Cash Quality] Cash and deposits 60.9B yen declined 26.8% YoY from 83.3B yen, indicating significant cash consumption. Short-term debt coverage calculated as cash to short-term borrowings stands at 9.6x, maintaining adequate liquidity despite cash decline. However, operating cash flow data is unavailable for quarterly periods, limiting assessment of cash generation quality. [Investment Efficiency] Asset turnover 0.59 times calculated as revenue 291.5B yen divided by total assets 497.1B yen reflects moderate asset utilization. Inventory turnover days 144.5 days calculated from inventory 78.0B yen exceeds industry norms, indicating inventory management challenges. Receivables turnover days 107.7 days calculated from trade receivables 86.0B yen also appears extended, suggesting collection efficiency issues. [Financial Health] Equity ratio 59.7% remains robust, providing financial stability cushion. Current ratio 293.3% calculated as current assets 243.2B yen to current liabilities 82.9B yen demonstrates strong short-term liquidity. Debt-to-equity ratio 0.17 calculated as interest-bearing debt 51.4B yen to equity 296.8B yen indicates conservative leverage, though long-term loans increased 31.9% to 40.5B yen suggesting changing capital structure.
Cash and deposits decreased 22.4B yen YoY to 60.9B yen, representing 26.8% decline and indicating material cash outflows during the period. Operating profit growth of 24.6B yen in revenue did not translate to cash accumulation, suggesting cash consumption through working capital expansion, investment activities, or financing outflows. Working capital movements show inventory increased 13.8B yen to 78.0B yen and trade receivables increased 19.8B yen to 86.0B yen, together representing 33.6B yen working capital expansion that consumed operating cash. Trade payables increased 3.8B yen to 27.5B yen, providing partial offset through supplier credit extension but insufficient to compensate receivables and inventory growth. The working capital expansion indicating inventory buildup and receivables elongation suggests either sales growth requiring higher working capital investment or efficiency deterioration in asset management. Intangible assets increased 16.2B yen to 57.8B yen and goodwill increased 5.8B yen to 29.9B yen, reflecting business acquisitions consuming cash for M&A activities. Long-term loans increased 9.8B yen to 40.5B yen while short-term borrowings decreased 6.0B yen to 6.4B yen, indicating debt refinancing from short to long-term and potentially funding portion of acquisition costs. Cash coverage of current liabilities at 60.9B yen cash against 82.9B yen current liabilities provides 0.73x coverage, adequate when combined with operating cash generation but requiring monitoring given cash decline trend. The net cash reduction despite revenue growth and debt increase suggests significant cash deployment in business expansion and working capital, with liquidity remaining adequate but trending toward tighter cash positions.
Ordinary income of 12.6B yen versus operating income of 12.6B yen shows minimal non-operating impact with net non-operating contribution near zero, comprising non-operating income 1.9B yen offset by non-operating expenses 2.0B yen. Non-operating income consisted primarily of dividend income 0.9B yen and interest income 0.5B yen, representing recurring financial income streams. Non-operating expenses included interest expense 1.1B yen on debt obligations. Non-operating items represent 0.7% of revenue at 1.9B yen income, indicating limited reliance on non-core financial activities. Extraordinary items totaling net 3.0B yen positive (extraordinary income 7.2B yen less extraordinary loss 4.2B yen) materially impacted net income, with gain on sale of securities 6.4B yen representing non-recurring divestment proceeds while impairment loss 3.9B yen in Takara Bio segment reflects asset write-downs. The extraordinary items represent 10.3% of ordinary income on net basis, indicating significant one-time factors influencing reported earnings. Income tax expense of 8.4B yen on profit before tax 15.6B yen resulted in 53.7% effective tax rate, substantially above Japan's statutory corporate tax rate of approximately 30%, suggesting non-deductible expenses including impairment charges and jurisdictional tax adjustments reducing earnings quality. Operating cash flow data is unavailable for quarterly reporting, preventing direct assessment of cash conversion ratio, though balance sheet cash decline of 22.4B yen against net income 7.2B yen suggests cash outflows exceeded reported earnings. The elevated non-recurring items, high effective tax rate, and cash decline relative to reported profit indicate earnings quality warrants monitoring, with core recurring profitability obscured by extraordinary factors.
Full-year guidance projects revenue 392.0B yen (YoY +8.1%), operating income 16.2B yen (YoY -21.3%), and ordinary income 15.7B yen (YoY -29.2%). Q3 cumulative progress rates against full-year guidance are revenue 74.4%, operating income 78.0%, and ordinary income 80.0%. Revenue progress of 74.4% trails the standard 75% benchmark by 0.6 percentage points, indicating slight underperformance requiring Q4 acceleration to 100.5B yen (34.5% of full-year) versus Q3 cumulative run-rate of 97.2B yen quarterly average. Operating income progress of 78.0% exceeds the standard 75% by 3.0 percentage points, suggesting conservative full-year guidance or stronger first three quarters performance. Ordinary income progress of 80.0% similarly exceeds standard by 5.0 percentage points. The guidance implies Q4 operating income of 3.6B yen and ordinary income of 3.1B yen, representing material sequential decline from Q3 cumulative quarterly average of 4.2B yen for both metrics, suggesting expected seasonal weakness or conservative buffer. EPS forecast 57.43 yen with dividend forecast 31.00 yen (including 2.00 yen commemorative dividend for 100th anniversary) indicates management confidence in meeting earnings targets despite year-to-date profit decline. No forecast revision was made during the current quarter, maintaining original guidance despite Q3 actual results. The forecast assumes recovery in Takara Bio segment performance and operating expense management improvement to moderate the profit decline trend observed year-to-date.
Annual dividend forecast 31.00 yen per share comprises ordinary dividend 29.00 yen plus commemorative dividend 2.00 yen for 100th anniversary, maintaining consistency with prior guidance. Payout ratio calculated at 57.9% based on forecast EPS 57.43 yen and dividend 31.00 yen, representing elevated distribution level relative to earnings. The payout ratio exceeds typical sustainable levels of 30-50%, though remains manageable given current balance sheet strength with equity ratio 59.7% and cash reserves 60.9B yen. The commemorative dividend 2.00 yen is non-recurring, implying normalized dividend of 29.00 yen would represent 50.5% payout ratio on forecast EPS. No share buyback program was disclosed for the current period. Total return ratio equals payout ratio at 57.9% in absence of buybacks, indicating shareholder returns concentrated in dividends. The dividend policy maintains stability despite earnings decline, suggesting management commitment to shareholder returns, though sustainability depends on cash flow generation improvement given operating cash flow unavailability and observed cash balance decline of 22.4B yen YoY. The elevated payout ratio combined with cash consumption trend warrants monitoring of dividend sustainability in future periods absent operational improvement.
Takara Bio segment structural losses with negative 17.1% operating margin and cumulative impairment charges 3.87B yen indicate significant business model challenges requiring turnaround strategy. The segment's persistent unprofitability despite parent company support represents material earnings drag, with potential for additional asset write-downs if performance deterioration continues. Continued losses may necessitate strategic review including potential restructuring, divestment, or capital injection decisions. Working capital efficiency deterioration evidenced by inventory turnover days 144.5 and receivables turnover days 107.7, both exceeding industry norms, indicates cash conversion cycle elongation to 218 days. The working capital expansion consumed estimated 33.6B yen cash through inventory and receivables growth outpacing payables, constraining liquidity despite strong balance sheet ratios. Failure to improve working capital management would pressure cash generation and potentially limit growth investment capacity or dividend sustainability. Goodwill and intangible assets totaling 87.8B yen (17.7% of total assets) including 29.9B yen goodwill and 57.8B yen intangibles concentrated in international acquisitions and bio-technology assets create future impairment risk. The provisional accounting for recent acquisitions (Kagerer 1.48B yen, Curio Bioscience 0.63B yen) indicates potential for allocation adjustments upon finalization. Given Takara Bio's current impairment history, elevated intangible asset base requires continuous performance monitoring to avoid additional write-downs that would further pressure profitability.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE 2.4% substantially underperforms industry median 5.2% (2025-Q3), positioning in bottom quartile. Operating margin 4.3% trails industry median 4.9% and falls below first quartile 3.4%, indicating competitive disadvantage in operational efficiency. Net profit margin 2.5% also lags industry median 3.4%, reflecting combined impact of operating inefficiency and elevated tax burden. Return on invested capital below industry median 5.0% suggests suboptimal capital deployment efficiency.
Financial Health: Equity ratio 59.7% exceeds industry median 48.0% and approaches third quartile 61.3%, demonstrating conservative capital structure and strong solvency position. Current ratio 293.3% significantly exceeds industry median 176.0% and third quartile 238.0%, indicating superior short-term liquidity though potentially excessive cash holdings prior to recent decline. Net debt to EBITDA positioning unavailable but implied favorable given low leverage ratio.
Efficiency: Asset turnover 0.59 times closely aligns with industry median 0.61, indicating peer-level asset utilization efficiency. However, inventory turnover days 144.5 and receivables turnover days 107.7 both exceed industry median benchmarks (inventory 51.1 days, receivables 71.2 days), highlighting working capital management as key operational weakness. Operating working capital turnover days materially exceed industry median 62.1 days, confirming cash conversion cycle inefficiency.
Growth: Revenue growth 9.2% YoY significantly exceeds industry median 3.8% and third quartile 5.1%, positioning in top quartile for top-line expansion. However, EPS declined while industry median shows 16% EPS growth, indicating profit growth disconnect. The Rule of 40 metric (growth plus profitability) estimated at 13% trails industry median 8% primarily due to negative profit contribution offsetting revenue growth strength.
※ Industry: Food & Beverage (13 companies), Comparison: 2025-Q3 period, Source: Proprietary analysis
Revenue growth momentum of 9.2% YoY positions Takara Holdings in top quartile of food and beverage industry peers, driven primarily by Takara Shuzo International Group expansion including strategic M&A execution. However, operational efficiency deterioration manifested through 1.3 percentage point operating margin compression and elevated SG&A ratio growing faster than revenue indicates scale benefits are not materializing, requiring management focus on cost structure optimization and integration synergy realization from recent acquisitions. Structural profitability challenges in the Takara Bio segment with persistent losses and cumulative impairment charges of 3.9B yen signal need for strategic repositioning or potential exit considerations. The segment's negative contribution offsets otherwise stable alcoholic beverage operations, representing key turnaround priority for consolidated earnings recovery. Working capital management requiring immediate attention with inventory days 144.5 and receivables days 107.7 both significantly exceeding industry benchmarks, resulting in cash conversion cycle of 218 days that constrains cash generation despite revenue growth. The 22.4B yen cash decline YoY while revenue expanded indicates operational cash conversion weakness, with working capital absorption of estimated 33.6B yen requiring operational discipline to restore cash flow generation supporting dividend sustainability at elevated 57.9% payout ratio.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.